A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs INCB 057643 (Primary)
- Indications Haematological malignancies; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 01 Aug 2017 According to an Incyte Corporation media release, data expected to be presented at medical meetings in the second half of 2017.
- 09 May 2017 Planned number of patients changed from 155 to 230.
- 08 Jun 2016 Status changed from not yet recruiting to recruiting.